Wellcome Sanger Institute

Parts HipSci

Measuring the variability in human gene essentiality across healthy individuals. The project involves performing whole genome CRISPR-Cas9 screens in multiple HipSci cell lines. 

Genes do not function the same way in different individuals. This variability is caused by genetic modifiers scattered throughout the genome, and environmental ones modulating the cells in non-heritable ways. As a most basic question, it is not known to which extent gene essentiality (here defined as its requirement for survival and fitness) varies in healthy humans.

We propose to quantify the effect of all single gene knock-outs on fitness in induced pluripotent stem cells from healthy donors. This will provide a collection of genes that vary in essentiality due to genetic background, and can be followed up with targeted screens for common variant modifiers.

The first part of the project concluded at the end of last year.  In total, 46 individual cell lines were processed, including 36 completed screens.  We obtained data from 23 individual donors and completed 11 donor pairs of cell lines.

The next phase of the project is performing some research and development, investigating whether alternative screen strategies scale, and give high quality data.  The two methods being compared are CRISPRi and Guide swap.  Once the best strategy has been selected, this method will then be used to perform genome-scale screens in the entire feasible HIPSCI cohort to map modifiers of gene essentiality.

Sanger people

Photo of Dr Adam Hunter

Dr Adam Hunter

Senior Scientific Manager

Photo of Verity Goodwin

Verity Goodwin

Advanced Research Assistant

Photo of Dr Leopold Parts

Dr Leopold Parts

Group Leader